TopiVert To Present First In Human Data From Its Phase I Clinical Study With TOP1288 At DDW 2016 In San Diego
Published: May 09, 2016
LONDON, UNITED KINGDOM--(Marketwired - May 09, 2016) - TopiVert Pharma Ltd ("TopiVert" or the "Company"), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory diseases of the gastrointestinal tract and eye, announces that it will present posters on the Phase I study data results and pre-clinical pharmacology for TOP1288, its lead compound for the treatment of ulcerative colitis (UC), a form of inflammatory bowel disease (IBD), at the Digestive Disease Week (DDW) 2016 in San Diego, California, from 21-24 May.
Senior members of the management and R&D teams will be available at the conference to discuss the data with interested parties. The posters to be presented are:
- A first-in-human randomized double-blind placebo-controlled clinical trial of a novel narrow spectrum kinase inhibitor. Rowley et al.
- TOP1210 NSKI Demonstrates Superior Activity and Improved Safety Profile Potential Compared to Corticosteroid and Immunomodulators in Preclinical Models of Colitis. Walshe et al.
- Inhibition of cytokine release from HT-29 cells and ulcerative colitis biopsies is potentiated by combination of selective kinase inhibitors and such effects are mimicked by TOP1210, a Narrow spectrum kinase inhibitor (NSKI). Foster et al.
- Effects of TOP1210, a narrow spectrum kinase inhibitor, and selective kinase inhibitors on the intestinal pro-inflammatory immune response in ulcerative colitis. Foster et al.
The posters are all available at www.topivert.com/our-science-publications
Click on, or paste the following link into your web browser, to view the associated PDF document.
This information is provided by RNS
The company news service from the London Stock Exchange